Dr. Shab has just joined us as the President of 42Bio, Inc!
She is the former Vice President of Research and Development for VIVEX Biologics, Inc. She was responsible for leading product development of all cell and tissue-based products for the company. In addition, Dr. Namin was an important member of the commercialization team. Her main interests are the development of regenerative therapies focused around stem cell derived allografts as well as amniotic derived tissue products. As such, Dr. Namin played an integral role in developing and commercializing VIVEX’s viable stem cell allografts and amniotic tissue offerings. At her tenure with VIVEX, she successfully launched 14 new products and line extensions.
Dr. Namin received her Bachelors and PhD in Biomedical Engineering from Florida International University. In addition, she received an MBA and MS in Industrial Engineering from the University of Miami and an MS in Biotechnology from Harvard University. During her early studies, Dr. Namin spent several years working in many different facets in the tissue engineering realm, focusing on the commercialization of cell and tissue-based products. She has multiple publications and patents for her work on the development of these therapies. She is currently the Chair of the Scientific & Technical Affairs Committee (STAC) for the American Association of Tissue Banks.